Select Publications

Allegra CJ et al. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc ASCO 2008;Abstract 4006.

Bokemeyer C et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. Proc ASCO 2008;Abstract 4000.

Ciuleanu TE et al. A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). Proc ASCO 2008;Abstract 4032.

Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371(9617):1007-16. Abstract

Samalin E et al. Interim analysis of a multicenter phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU + irinotecan + oxaliplatin) as first-line treatment of metastatic colorectal cancer (mCRC) patients. Gastrointestinal Cancers Symposium 2008;Abstract 375.

Tabernero J et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25(33):5225-32. Abstract

Van Cutsem E et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Proc ASCO 2008;Abstract 2.

Ychou M et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008;62(2):195-201. Abstract